Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease
Pharmaceutical Technology
APRIL 3, 2023
The firm is also entitled to receive up to $410m for future development and regulatory and commercial milestones, provided these are attained within the timeline of the deal. In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.
Let's personalize your content